argenex SE $ARGX Stock Holdings Trimmed by First Trust Advisors LP

First Trust Advisors LP lessened its holdings in shares of argenex SE (NASDAQ:ARGX) by 4.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 58,770 shares of the company’s stock after selling 2,630 shares during the quarter. First Trust Advisors LP’s holdings in argenex were worth $32,395,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. WPG Advisers LLC bought a new position in argenex in the 1st quarter valued at about $37,000. Brooklyn Investment Group boosted its holdings in shares of argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after acquiring an additional 38 shares in the last quarter. MAI Capital Management increased its stake in shares of argenex by 866.7% during the second quarter. MAI Capital Management now owns 87 shares of the company’s stock valued at $48,000 after acquiring an additional 78 shares during the period. Banque Transatlantique SA bought a new stake in argenex during the first quarter worth approximately $62,000. Finally, Geneos Wealth Management Inc. lifted its position in argenex by 550.0% in the first quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after purchasing an additional 99 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on ARGX. Morgan Stanley boosted their price objective on argenex from $1,070.00 to $1,110.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. Bank of America boosted their price target on shares of argenex from $880.00 to $887.00 and gave the stock a “buy” rating in a research report on Tuesday, September 2nd. Guggenheim restated a “buy” rating and set a $1,070.00 price objective on shares of argenex in a research report on Thursday, September 18th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Finally, TD Cowen increased their target price on shares of argenex from $800.00 to $1,146.00 and gave the company a “buy” rating in a research note on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $917.39.

argenex Trading Up 0.1%

ARGX stock opened at $890.11 on Thursday. argenex SE has a one year low of $510.05 and a one year high of $934.62. The firm has a 50-day moving average of $859.76 and a two-hundred day moving average of $713.03. The firm has a market capitalization of $54.80 billion, a PE ratio of 38.22, a P/E/G ratio of 0.89 and a beta of 0.37.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.37 by $0.03. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. argenex had a net margin of 41.58% and a return on equity of 29.78%. On average, equities research analysts anticipate that argenex SE will post 3.13 earnings per share for the current year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.